Financials Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977022039

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
3.910 ^USD	-3.46%		-9.07%	-28.49%

03-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-22	Alert wrongly tagged to Bolt Biotherapeutics Inc withdrawn	RE

Projected Income Statement: Bolt Biotherapeutics, Inc.

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Net sales ¹	1.26	5.729	7.876	7.69	7.695	2.333	14.53	19.33
Change	-	354.68%	37.48%	-2.36%	0.07%	-69.68%	522.57%	33.09%
EBITDA	-83.1	-79.08	-65.12	-	-	-	-	-
Change	-	4.83%	17.65%	-	-	-	-	-
EBIT ¹	-92.79	-90.32	-76.2	-73.05	-36.11	-47.45	-42.02	-44.08
Change	-	2.66%	15.64%	4.13%	50.56%	-31.39%	11.44%	-4.91%
Interest Paid	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-98.59	-88.1	-69.2	-63.12	-33.38	-21.28	-32.74	-16.97
Change	-	10.64%	21.45%	8.79%	47.12%	36.23%	-53.84%	48.18%
Net income ¹	-98.59	-88.1	-69.2	-63.12	-33.38	-40.43	-26.75	-25.66
Change	-	10.64%	21.45%	8.79%	47.12%	-21.14%	33.85%	4.08%
Announcement Date	30/03/22	29/03/23	21/03/24	24/03/25	12/03/26	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3	2027 Q4
Net sales ¹	-	-	0.752	0.508	0.813	1.393	2.112	1.411	1.826	1.433	2.528	2.089	5.274	1.275	1.141	-	1.222	1.804	2.169	2.5	1.5	1.5	1.5	1.5	-	-	-	-
Change	-	-	-	-32.45%	60.04%	71.34%	51.62%	-33.19%	29.41%	-21.52%	76.41%	-17.37%	152.47%	-75.82%	-10.51%	-	-	47.63%	20.23%	15.26%	-40%	0%	0%	0%	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBIT ¹	-18.43	-23.76	-23.53	-27.08	-23.88	-23.06	-22.35	-21.04	-18.42	-19.83	-18.18	-19.77	-17.09	-22.6	-16.44	-16.92	-12.12	-9.21	-7.703	-7.085	-6.487	-6.373	-6.264	-6.159	-	-	-	-
Change	-	-28.95%	0.99%	-15.09%	11.82%	3.42%	3.09%	5.84%	12.48%	-7.69%	8.31%	-8.71%	13.53%	-32.21%	27.23%	-2.88%	28.38%	23.98%	16.36%	8.02%	8.44%	1.76%	1.71%	1.68%	-	-	-	-
Charge d'intérêts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-24.45	-23.58	-23.4	-27.16	-23.68	-22.66	-21.76	-20	-16.98	-18.06	-16.26	-17.9	-10.81	-21.2	-15.18	-15.94	-11.04	-8.561	-7.144	-6.631	-5.487	-5.373	-5.264	-5.159	-	-	-	-
Change	-	3.55%	0.81%	-16.08%	12.81%	4.28%	3.99%	8.1%	15.09%	-6.34%	9.97%	-10.12%	39.61%	-96.05%	28.4%	-5.01%	30.72%	22.45%	16.55%	7.18%	17.25%	2.08%	2.03%	1.99%	-	-	-	-
Net income ¹	-24.45	-23.58	-23.4	-27.16	-23.68	-22.66	-21.76	-20	-16.98	-18.06	-16.26	-17.9	-10.81	-21.2	-15.18	-15.94	-11.04	-8.561	-7.144	-6.631	-5.487	-5.373	-5.264	-5.159	-	-	-	-
Change	-	3.55%	0.81%	-16.08%	12.81%	4.28%	3.99%	8.1%	15.09%	-6.34%	9.97%	-10.12%	39.61%	-96.05%	28.4%	-5.01%	30.72%	22.45%	16.55%	7.18%	17.25%	2.08%	2.03%	1.99%	-	-	-	-
Announcement Date	13/05/21	12/08/21	09/11/21	30/03/22	12/05/22	10/08/22	10/11/22	29/03/23	11/05/23	07/08/23	09/11/23	21/03/24	14/05/24	13/08/24	12/11/24	24/03/25	12/05/25	14/08/25	12/11/25	12/03/26	-	-	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Bolt Biotherapeutics, Inc.

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Net Debt	-186	-146	-82	-	-	-	-	-
Change	-	21.51%	43.84%	-	-	-	-	-
Announcement Date	30/03/22	29/03/23	21/03/24	24/03/25	12/03/26	-	-	-

Estimates

Cash Flow Forecast: Bolt Biotherapeutics, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025
CAPEX ¹	3.262	2.338	1.953	0.206	0.041	0.072
Change	-	-28.33%	-16.47%	-89.45%	-80.1%	75.61%
Free Cash Flow (FCF) ¹	-29.22	-41.99	-46.18	-39.47	-37.54	-23.34
Change	-	-43.73%	-9.97%	14.54%	4.88%	37.82%
Announcement Date	31/03/21	30/03/22	29/03/23	21/03/24	24/03/25	12/03/26

¹USD in Million

Estimates

Forecast Financial Ratios: Bolt Biotherapeutics, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027	2028
Profitability
EBITDA Margin (%)	-	-6,594.84%	-1,380.33%	-826.8%	-	-	-	-	-
EBIT Margin (%)	-	-7,364.13%	-1,576.56%	-967.45%	-949.91%	-469.3%	-2,033.56%	-289.27%	-228.03%
EBT Margin (%)	-	-7,824.68%	-1,537.76%	-878.58%	-820.78%	-433.74%	-912.13%	-225.39%	-87.76%
Net margin (%)	-	-7,824.68%	-1,537.76%	-878.58%	-820.78%	-433.74%	-1,732.86%	-184.13%	-132.7%
FCF margin (%)	-	-	-	-	-	-	-	-	-
FCF / Net Income (%)	-	-	-	-	-	-	-	-	-
Profitability
ROA	-64.72%	-32.74%	-21.08%	-24.57%	-32.88%	-27.68%	-	-	-
ROE	-212.22%	-71.52%	-41.79%	-48.69%	-74.28%	-79.75%	-	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	-	34.09%	2.62%	-	-	-	-	-
CAPEX / EBITDA (%)	-	-	-2.47%	-0.32%	-	-	-	-	-
CAPEX / FCF (%)	-	-	-	-	-	-	-	-	-
Items per share
Cash flow per share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	133.8	90.75	59.16	-	-	-	-	-
Change	-	-	-32.15%	-34.81%	-	-	-	-	-
EPS ¹	-	-59.4	-47.2	-36.6	-33	-17.85	-17.86	-10.38	-11.35
Change	-	-	20.54%	22.46%	9.84%	45.91%	-0.03%	41.87%	-9.31%
Nbr of stocks (in thousands)	-	1,864	1,883	1,898	1,914	1,919	1,922	1,922	1,922
Announcement Date	-	30/03/22	29/03/23	21/03/24	24/03/25	12/03/26	-	-	-